4882 Stock Overview
A drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Perseus Proteomics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥723.00 |
| 52 Week High | JP¥876.00 |
| 52 Week Low | JP¥291.00 |
| Beta | 0.70 |
| 11 Month Change | 24.44% |
| 3 Month Change | -8.02% |
| 1 Year Change | -2.17% |
| 33 Year Change | 59.96% |
| 5 Year Change | n/a |
| Change since IPO | -16.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4882 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 6.3% | -1.9% | -0.5% |
| 1Y | -2.2% | 16.9% | 10.8% |
Return vs Industry: 4882 underperformed the JP Biotechs industry which returned 16.9% over the past year.
Return vs Market: 4882 underperformed the JP Market which returned 10.8% over the past year.
Price Volatility
| 4882 volatility | |
|---|---|
| 4882 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4882's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4882's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 25 | Takuya Yokokawa | www.ppmx.com |
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate.
Perseus Proteomics Inc. Fundamentals Summary
| 4882 fundamental statistics | |
|---|---|
| Market cap | JP¥10.66b |
| Earnings (TTM) | -JP¥966.00m |
| Revenue (TTM) | JP¥109.00m |
97.8x
P/S Ratio-11.0x
P/E RatioIs 4882 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4882 income statement (TTM) | |
|---|---|
| Revenue | JP¥109.00m |
| Cost of Revenue | JP¥11.00m |
| Gross Profit | JP¥98.00m |
| Other Expenses | JP¥1.06b |
| Earnings | -JP¥966.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -65.53 |
| Gross Margin | 89.91% |
| Net Profit Margin | -886.24% |
| Debt/Equity Ratio | 0% |
How did 4882 perform over the long term?
See historical performance and comparison